Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

DCTH - Delcath Systems, Inc. Latest News | Finranks

Home

DCTH

D

Delcath Systems, Inc. (DCTH)

NCM – Real Time Price. Currency in USD

8.97

-0.16 (-1.75%)

At close: Mar 27, 2026, 4:00 PM EDT

8.97

0.00 (0.00%)

After-hours: Mar 27, 2026, 4:10 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of the full results from the investigator-initiated CHOPIN randomized Phase 2 clinical trial, led by Principal Investigator Professor Ellen Kapiteijn, MD, from Leiden University Medical Center's Department of Medical Oncology. The publication, titled “Percutaneous.

Delcath: Fundamentals Intact, Despite Share Price Weakness

Delcath: Fundamentals Intact, Despite Share Price Weakness

Delcath Systems, Inc.'s revenue remains under pressure due to weak patient starts in the third quarter of 2025. The fundamentals of the company remain intact, though, and 2026 should be another year of strong growth. Delcath's profitability will be under pressure due to investments in clinical trials and sales and marketing.

Delcath Systems, Inc. (DCTH) Q4 2025 Earnings Call Transcript

Delcath Systems, Inc. (DCTH) Q4 2025 Earnings Call Transcript

Delcath Systems, Inc. (DCTH) Q4 2025 Earnings Call Transcript

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Results Total fourth quarter and full year revenue of $20.7 million and $85.2 million, respectively HEPZATO KIT™ fourth quarte.

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on February 26, 2026, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Th.

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference at the Cliff Lodge in Snowbird, Utah. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatmen.

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either November 2025 or December 2025. The grants, in the form of Restricted Stock Units (RSUs), totaled.

Videos

No Data

There is no data to display

Press releases

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of the full results from the investigator-initiated CHOPIN randomized Phase 2 clinical trial, led by Principal Investigator Professor Ellen Kapiteijn, MD, from Leiden University Medical Center's Department of Medical Oncology. The publication, titled “Percutaneous.

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Results Total fourth quarter and full year revenue of $20.7 million and $85.2 million, respectively HEPZATO KIT™ fourth quarte.

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference at the Cliff Lodge in Snowbird, Utah. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatmen.

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either November 2025 or December 2025. The grants, in the form of Restricted Stock Units (RSUs), totaled.